Health
Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC – MedPage Today
More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab.
Neoadjuvant combination immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) produced a significant clinical benefit for patients with operable stage I-III non-small cell lung cancer (NSCLC), researchers reported.
The phase II NEOSTAR study randomly assigned 44 patients with operable NSCLC to neoadjuvant nivolumab with or without ipilimumab followed by surgery. Among those, 38% of patients that received the combination achieved major pathological response (MPR) — defined as 10% or less…
-
Noosa News21 hours agoFatal Traffic Crash, South Bingera
-
General23 hours agoBathurst 1000 quick hits: Chaz Mostert drinks beer with fans, Erebus owner protests, and drama on Mount Panorama
-
Noosa News17 hours agoTrucking company penalised for refusing to pay unfairly sacked worker
-
Noosa News13 hours agoFarmgate Backpackers leads with integrity amid industry challenges